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T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of diffuse large B-cell lymphoma, and has
been reported to mainly affect lymph nodes with advanced Ann Arbor stage. We present a 69-year-old woman
with a past history of chronic thyroiditis, who had suffered from rapidly-growing thyroid tumor. No other lymph
nodes swelling or extranodal lesions were detected. She promptly underwent surgery with resection of the thyroid
tumor, and the diagnosis of THRLBCL was established pathologically. She was successfully treated by standard
rituximab-containing chemotherapy. To our knowledge, this is the first case report of THRLBCL exclusively arising in
the thyroid.
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A 69-year-old woman was admitted to our hospital due to
difficulty in breathing and thyroid tumor that had grown
rapidly over a period of 1 month. The patient had a past
history of chronic thyroiditis, which was diagnosed a year
before on the basis of positive anti-thyroglobulin antibody
and elevation of thyroid stimulating hormone with
enlarged thyroid. The disease had been well controlled with
levothyroxine supplementation. Computed tomography
(CT) scan showed a diffuse and massive thyroid tumor nar-
rowing the tracheal lumen (Figure 1a). No other tumors,
lymphadenopathy, or hepatosplenomegaly were detected.
There were no B symptoms. Due to the risk of sudden air-
way obstruction, urgent hemithyroidectomy and tracheal
tube insertion were performed. Rapid frozen section diag-
nosis of the resected thyroid tumor suggested the possibility
of lymphoma, and administration of prednisolone (PSL)
was performed after the operation. The remaining thyroid
tumor had reduced to some extent, and the patient’s
general condition and respiratory state recovered well.
Thorough pathological examination of the thyroid tumor
revealed scattered neoplastic large B-lymphocytes, which
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reproduction in any medium, provided the orand surrounding abundant T-lymphocytes (CD3+) and
histiocytes (CD68+) (Figure 1b – 1f). In situ hybridization
for Epstein-Barr virus-encoded RNA (EBER) was negative.
According to the above findings, the diagnosis of T-cell/his-
tiocyte-rich large B-cell lymphoma (THRLBCL) was estab-
lished. Gallium scintigraphy showed increased gallium
uptake in the thyroid with no other abnormal signals
(Figure 1g). Bone marrow aspiration/biopsy revealed no
infiltration of lymphoma cells. Serum lactate dehydrogenase
was within the normal limits (217 IU/L), and soluble
interleukin-2 receptor was slightly elevated (639 U/mL).
The clinical stage was IE, and the patient was classified as
being at low-intermediate risk according to the inter-
national prognostic index. She was successfully treated by
chemotherapy consisting of rituximab, cyclophosphamide,
doxorubicin hydrochloride, vincristine, and PSL (R-CHOP)
without any major issues including tracheal problems.
Complete response was confirmed after the completion of
six courses of R-CHOP regimen.
THRLBCL is a rare morphological subtype of diffuse
large B-cell lymphoma (DLBCL), which is characterized by
a limited number of scattered, large, atypical B-cells embed-
ded in a background of abundant T-cells and frequently
histiocytes [1]. THRLBCL has been reported to mainly
affect lymph nodes, and most cases are at advanced Ann
Arbor stage with intermediate to high risk of IPI [1-3].
Although extranodal involvement of THRLBCL is not
uncommon, an exclusively extranodal presentation atl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 (1a) Computed tomography of the thyroid tumor. (1b) Microscopic examination of the thyroid revealed that the tumor is
comprised of scattered large atypical cells embedded in a background of histiocytes and small lymphocytes (hematoxylin and eosin staining).
(1c, 1d) The scattered atypical cells were positive for CD20 (1c) and CD79a (1d). (1e) Small lymphocytes represent CD3-positive T-cells. (1f)
Substantial numbers of CD68-positive histiocytes are also intermingled. (1g) Gallium scintigraphy showed increased gallium uptake in the thyroid
exclusively.
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of 61 cases investigated had lymph node lesions. In contrast
to these observations, our case had a single thyroid tumor
with an IPI score indicating low-intermediate risk. To our
knowledge, this is the first case report of THRLBCL exclu-
sively arising in the thyroid.
Malignant lymphoma is a minor component of thyroid
tumors, accounting for only 2 to 5% of all thyroid malig-
nancies. Thyroid lymphoma is often associated with
chronic thyroiditis, and mostly diagnosed as DLBCL and
MALT lymphoma pathologically [4]. Also in this case, the
past history of chronic thyroiditis might be associated with
the emergence of lymphoma.
THRLBCL is considered an aggressive lymphoma. It
has also been reported that THRLBCL with histiocytes
could represent a very aggressive lymphoma [1]. Al-
though the biological characteristics seem to be differ-
ent from DLBCL and the effects of rituximab for
THRLBCL remain to be determined, it is recom-
mended at present that THRLBCL should be treated
similar to stage-matched DLBCL [2]. On the other
hand, localized extranodal DLBCL is often treated with
radiation therapy with or without chemotherapy,
as reported in gastric lymphoma [5]. In this case,
however, a tracheotomy was done before lymphoma
treatment and radiation therapy could cause airway
trouble; so that the patient was treated with R-CHOP
chemotherapy without radiation. The patient described
here showed a good clinical course; however, carefulobservation is indispensable to monitor disease relapse
at both the primary site and distant sites.
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